Malignant tumor of urinary bladder
- Synonyms
- Bladder cancer; Urinary Bladder Neoplasms; Urinary bladder cancer
Summary
Available tests
Check Related conditions for additional relevant tests.
Clinical tests (141 available)
Cytogenetics Tests
Genes See tests for all associated and related genes
Also known as: ACH, CD333, CEK2, HSFGFR3EX, JTK4, FGFR3
Summary: fibroblast growth factor receptor 3Also known as: C-BAS/HAS, C-H-RAS, C-HA-RAS1, CTLO, H-RASIDX, HAMSV, HRAS1, RASH1, p21ras, HRAS
Summary: HRas proto-oncogene, GTPaseAlso known as: 'C-K-RAS, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A, K-RAS4B, K-Ras, K-Ras 2, KI-RAS, KRAS1, KRAS2, NS, NS3, OES, RALD, RASK2, c-Ki-ras, c-Ki-ras2, KRAS
Summary: KRAS proto-oncogene, GTPaseAlso known as: OSRC, PPP1R130, RB, p105-Rb, p110-RB1, pRb, pp110, RB1
Summary: RB transcriptional corepressor 1
Clinical features
Help- Neoplasm
- Bladder neoplasm
Bladder neoplasm
- MedGen UID: 594
- Concept ID: C0005695
- Finding: Neoplastic Process
Neoplasm
- Transitional cell carcinoma of the bladder
Transitional cell carcinoma of the bladder
- MedGen UID: 76013
- Concept ID: C0279680
- Finding: Neoplastic Process
Neoplasm
- Bladder neoplasm
- NCCN, 2024NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Bladder Cancer, 2024
- NICE, 2023UK NICE Guideline NG12, Suspected cancer: recognition and referral, 2023
IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.